Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1541 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Exostoses, Multiple, Type II | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| EXT2 | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Exostoses, multiple, type I & II - Multiple exostoses type I (EXT1; MIM 133700) and type II (EXT2; MIM 133701) are autosomal dominant disorders characterized by multiple osteochondromas (MO). Osteochondromas are benign, cartilage-capped bone tumors. Multiple osteochondromas arise from growth plates and are most numerous in the juxta-epiphyseal region of long tubular bones but also may occur from surfaces of flat bones, vertebrae and ribs. Complications associated with osteochondromas include compression of nerves, tendons and blood vessels, short stature and deformities of bones leading to functional problems. Considerable inter- and intrafamilial phenotypic variability is observed in MO. Chondrosarcomas resulting in malignant transformation of osteochondromas occurs in about 1-5% of patients. MO is caused by mutations in two genes, exostosin 1 (EXT1) and exostosin 2 (EXT2). The products of these two genes are involved in the synthesis of heparin sulfate proteoglycans. EXT1 and EXT2 are also considered to have tumor suppressor gene functions. In general, a more severe phenotype has been associated with EXT1 mutations. Deletion of the EXT1 and TRPS1 genes results in trichorhinophalangeal syndrome, type II (TRPS2; MIM 150230). TRPS2 is also known as Langer-Giedion syndrome (LGS). TRPS2 is a contiguous gene syndrome with the combined clinical features of trichorhinophalangeal syndrome, type I and multiple exostoses type I. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| EXT2 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 133701 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Skeletal Disorders | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.